Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Terminated 3Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Myeloproliferative Disorders 3Primary Myelofibrosis 1Blast Crisis 1

Interventions

Cyclophosphamide 14fludarabine phosphate 13ruxolitinib 9Busulfan 9Antilymphocyte Serum 9fludarabine 8Peripheral Blood Stem Cell Transplantation 8Filgrastim 8Whole-Body Irradiation 7Cyclosporine 7Tacrolimus 6Radiotherapy 6Mycophenolic Acid 6Methylprednisolone 6Methotrexate 5Melphalan 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Azacitidine 5Imatinib Mesylate 4Alemtuzumab 4ponatinib 3parsaclisib 3fedratinib 3Stem Cell Transplantation 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Decitabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Myeloproliferative Disorders × fedratinib × Clear all
NCT05127174 2025-12-04

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
12 enrolled
Myeloid

Myeloproliferative Disorders

NCT03755518 2024-12-12

FREEDOM

Celgene

Phase 3 Terminated
38 enrolled 23 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Columbia University

Phase 1 Terminated
2 enrolled
Myeloid

Blast Crisis, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡